MEN1 and leukemia: Given that the interaction of menin and KMT2A protein is essential in initiating the oncogenesis of HOXA9-driven leukemia, menin-KMT2A inhibitors are promising molecular-targeting agents applicable to a considerable proportion of AML patients.